BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250923T100000
DTEND;TZID=Europe/Paris:20250923T100000
DTSTAMP:20260416T195125
CREATED:20250911T075630Z
LAST-MODIFIED:20250911T075630Z
UID:187869-1758621600-1758621600@www.bordeaux-neurocampus.fr
SUMMARY:Seminar - Rob Meijers
DESCRIPTION:Venue: Centre Broca \n\nRob Meijers \nHarvard University \nInvited by Jonathan Elegheert (IINS) \nTitle\nDeveloping synthetic antibody reagents for neuronal receptors and their ligands \nAbstract\nThe Institute for Protein Innovation is a non-profit organization developing recombinant antibody panels targeting the human and mouse neuronal surfaceome. We focus on neurobiological pathways where there is a need for validated\, reproducible reagents.\nUsing display technologies and machine learning\, we systematically generate antibody panels that cover entire receptor families. This approach reduces antibody cross-reactivity and produces large\, consistent sequence datasets that can be used for machine learning applications to further develop and optimize these antibodies.\nOur synaptic cleft panel includes antibodies for receptor families like Neurexins\, Neuroligins\, Teneurins\, Latrophilins and Eph receptors. We are also developing panels for axon guidance receptor/ligand families and for glial cell markers. We are mapping cross-family interactions and identifying how they can be modulated using our antibodies. Each reagent is evaluated for binding kinetics\, potency\, specificity\, and aggregation\, and formulated as chimeric human/rabbit antibodies.\nThese antibodies are distributed through Addgene following community validation. We are establishing a crowdsourced validation system with Addgene to build a reliable set of reagents supporting studies in neuronal migration and synaptogenesis. We also welcome input on additional targets that would benefit the field. \nBiosketch\nDr. Rob Meijers is the Head of Neuroscience at the Institute for Protein Innovation (IPI)\, a non-profit organization dedicated to advancing protein science and technology in Boston\, United States. At IPI\, he leads efforts to develop renewable recombinant antibodies by combining synthetic biotechnology with machine learning protocols. The goal is to produce and distribute well-validated affinity reagents to support the life sciences community. Dr. Meijers’ team focuses on creating antibody panels for neuroscience applications\, enabling the study of synapse formation\, axon guidance\, and other neural processes that require novel protein tools. He also is as a part-time lecturer at Harvard Medical School. \n  \n
URL:https://www.bordeaux-neurocampus.fr/en/event/seminar-rob-meijers/
CATEGORIES:For scientists,home-event,IINS,Impromptu seminar
END:VEVENT
END:VCALENDAR